-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Linperlisib (YY-20394 tablets) significantly improves the treatment efficiency of relapsed/refractory follicular lymphoma and significantly reduces the incidence of adverse reactions.
On March 29, 2021 Beijing time, Shanghai Yingli Pharmaceutical Co.
, Ltd.
(abbreviated as Yingli Pharmaceutical) announced that its self-developed new drug Linperlisib for the treatment of relapsed/refractory follicular lymphoma phase 2 registration clinical trial has been completed.
The test results show that Linperlisib has achieved statistical and clinical significance improvements in terms of effectiveness and safety for the intention-to-treat population.
Outcome 1: Linperlisib is highly effective in treating relapsed/refractory follicular lymphoma Linperlisib has shown significant clinical benefits in subjects with relapsed/refractory follicular lymphoma.
The results of independent data evaluation (according to the evaluation standard IRWG for lymphoma efficacy) showed that Linperlisib had an ORR of over 80% in 89 patients (evaluable cases) with relapsed/refractory follicular lymphoma, and the disease control rate (DCR) Up to 95% or more.
Dr.
Xu Zusheng, President of R&D of Yingli Pharmaceuticals, said: “We are very excited to observe that Linperlisib has demonstrated extraordinary therapeutic effects in the treatment of relapsed/refractory follicular lymphoma.
The performance in the tumor clinical research project is full of confidence.
We look forward to bringing this Zhangjiang original
PI3Kδ inhibitor drug to patients around the world.
The result 2: Linperlisib is safe, controllable and well tolerated.
From the analysis of statistical results, Linperlisib oral administration is safe, controllable and well tolerated.
Common gastrointestinal adverse reactions such as nausea and similar drugs are especially concerned about the incidence of adverse reactions such as diarrhea and liver toxicity, which are lower than those reported in the literature of the same target drugs.
Compared with traditional therapies, Linperlisib did not find side effects such as vomiting, alopecia, phlebitis, and cardiotoxicity, and rarely caused severe reduction of whole blood cells (neutrophils <0.
5×10^9/L, hemoglobin <60g/L , And platelets <20×10^9/L), the medication process generally does not require hospitalization for monitoring, and it is convenient to carry, which greatly improves the quality of life of patients.
Dr.
Bao Hanying, vice president of the clinical department of Yingli Pharmaceuticals, said: “There is no PI3Kδ inhibitor on the market in China.
The results of this phase 2 clinical trial show that Linperlisib is not only effective, but also gastrointestinal discomfort (diarrhea, nausea, etc.
), The incidence of adverse reactions such as elevated liver enzymes, hypertension, and hyperglycemia is also lower than the previous safety data of this type of drug.
We hope that this new PI3Kδ inhibitor can improve the condition of patients suffering from FL .
"blood Diseases hospital, Chinese Academy of Medical Sciences Professor Qiu Lugui said:" follicular lymphoma (FL) is the world's second most common type of lymphoma, indolent lymphoma is the most common, the incidence rate in non-Hodgkin's lymphoma Second to diffuse large B-cell lymphoma, it is easy to transform into diffuse large B-cell lymphoma and has a very high recurrence rate after remission.
In recent years, immunochemotherapy has gradually replaced chemotherapy and radiotherapy, and has shown good results for different types of lymphoma Clinical treatment effect, but its safety, persistence of drug effect and tumor indication selection are still facing bottlenecks.
Linperlisib's phase 2 clinical trial for the treatment of relapsed/refractory follicular lymphoma has achieved gratifying results, which also indicate this The new PI3Kδ selective inhibitor is expected to bring a new therapy for people suffering from this serious disease, and bring hope to these patients and their families.
" Linperlisib clinical research status Yingli Pharmaceutical plans to treat relapsed/refractory follicles with Linperlisib The results of the Phase 2 clinical trial of sexual lymphoma are communicated with multiple regulatory agencies around the world, and the data will be gradually announced.
Linperlisib received two orphan drug qualifications (CLL/SLL, FL) from the U.
S.
FDA in October 2018, and was approved to conduct Phase II clinical studies in the United States in May 2020; it was approved by China's NMPA (National Medical Products Administration) in September 2020 ) Identification of breakthrough therapy, based on this identification, the market application of this product for the treatment of relapsed/refractory follicular lymphoma can pass the priority review review and approval process to reduce the first round of review time from the 200 required for routine review.
The day is shortened to 130 days[1], which means that Linperlisib is expected to be marketed as soon as possible.
At the same time, Linperlisib's application for breakthrough therapy in the United States is also proceeding simultaneously.
A total of 10 Linperlisib clinical trials are currently being carried out in China and globally.
Linperlisib's completed and ongoing clinical trials include: Linperlisib's tolerability and pharmacokinetics in patients with relapsed or refractory B-cell hematological malignancies Phase I clinical study (China, N=25) Linperlisib in the treatment of relapsed and/ Or a single-arm, open, multi-center phase II clinical trial of patients with refractory follicular lymphoma (China, N=93) A single-arm, open, multi-center phase Ib clinical trial of Linperlisib in patients with advanced solid tumors (China, N =79) A phase Ib clinical trial of Linperlisib in the treatment of patients with relapsed and/or refractory peripheral T-cell lymphoma (China, N=39) A phase I clinical trial of material balance and biotransformation of Linperlisib in Chinese adult male healthy volunteers ( China, N=6) A single-center, randomized, open, 2-sequence, 2-cycle clinical study to evaluate the effects of a high-fat and high-calorie diet on the pharmacokinetics of a single oral administration of Linperlisib tablets in healthy volunteers (China, N=14) Linperlisib treatment Phase Ib clinical study of patients with relapsed and/or refractory B-cell hematological malignancies (China, N=40) Linperlisib combined with GEMOX in the treatment of patients with relapsed and/or refractory diffuse large B-cell lymphoma Center Phase 1b, Phase 2 clinical trial (China, N=28) A single-arm, open, multi-center phase II clinical trial of the efficacy and safety of Linperlisib in patients with relapsed and/or refractory peripheral T/NK cell lymphoma (China, not yet enrolled) Linperlisib is a single-arm, open, multi-center phase II clinical trial for patients with relapsed and/or refractory follicular lymphoma (United States, not yet enrolled) About Linperlisib Linperlisib is an oral PI3Kδ inhibitor, It is a Class 1 new drug developed by Shanghai Yingli Pharmaceutical Co.
, Ltd.
Preclinical data show that it can reduce the phosphorylation level of AKT protein by inhibiting the expression of PI3Kδ protein, thereby inducing cell apoptosis and inhibiting the proliferation of malignant B cells and primary tumor cell lines.
Linperlisib is currently undergoing clinical studies in addition to single-drug treatment for the study population, but also combined with other anti-tumor drugs, such as Linperlisib combined with GEMOX for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.
About YY-20394-002 The single-arm, open, multi-center phase II clinical trial of Linperlisib in the treatment of patients with relapsed and/or refractory follicular lymphoma aims to evaluate the effectiveness and safety of such patients.
The primary research endpoint is the overall response rate (ORR), which is assessed by the Independent Data Evaluation Committee (IRC); the secondary research endpoints include ORR (assessed by the investigator); duration of response (DOR); progression-free survival (PFS); 6 Monthly PFS rate; 12-month PFS rate; survival time (OS); disease control rate (DCR); time to response (TTR) and drug safety.
In the two-year-long trial, a total of 93 cases of relapsed and/or refractory follicular lymphoma that had progressed after receiving second-line or higher systemic treatment (receiving rituximab and at least one alkylating agent) were included patient.
From the analysis of statistical results, Linperlisib oral administration is safe, controllable and well tolerated.
Common gastrointestinal adverse reactions such as nausea and similar drugs pay special attention to the incidence of adverse reactions such as diarrhea and liver toxicity, which are lower than those reported in the literature of the same target drugs.
Compared with traditional therapies, Linperlisib did not find side effects such as vomiting, alopecia, phlebitis, and cardiotoxicity, and rarely caused severe reduction of whole blood cells (neutrophils <0.
5×10^9/L, hemoglobin <60g/L , And platelets <20×10^9/L), the medication process generally does not need to be hospitalized for monitoring, and it is convenient to carry, which greatly improves the patient’s quality of life.
About Follicular Lymphoma (FL) Follicular lymphoma (FL) is a type of indolent non-Hodgkin's lymphoma (NHL) that originates in the follicular germinal center.
In my country, FL accounts for about 8.
1%~23.
5% of NHL, the median age of onset is 55~60 years old, and the incidence of women is slightly higher than that of men [2].
The disease progresses indolently, with a median survival of up to more than 10 years, but most diseases will eventually relapse or transform, and they still cannot be cured [3].
Research in 2018 showed that the survival of patients decreased significantly with the increase in the number of recurrences [4].
According to statistics, nearly 15% of patients in FL do not need treatment after the onset of disease, and nearly 20% of patients are refractory FL, with a very short survival period [5, 6]; in addition, nearly 30% of patients will Transformation into highly aggressive lymphoma is clinically manifested as the rapid progression of the disease and requires high-intensity treatment [7, 8].
At present, the first and second-line regimens for FL treatment recommended by major guidelines mainly target CD20 monoclonal antibody-based immunochemotherapy regimens, followed by CD20 monoclonal antibody maintenance treatment, and some relapsed patients can further obtain long-term survival through autologous stem cell transplantation.
[9].
In recent years, the "no chemotherapy" regimen for FL has attracted more and more attention because of its definite efficacy and low toxicity.
Current research hotspots for relapsed/refractory FL are new targeted drugs and immunotherapy, including PI3K inhibitors, BCL2 inhibitors, EZH2 inhibitors, bispecific antibodies, chimeric antigen receptor T cell (CAR-T) therapy, etc.
. Reference materials: [1] State Administration for Market Regulation, Drug Registration Management Measures (2020 Edition).
[2] Chinese Medical Association Hematology Branch, Chinese Anti-Cancer Association Lymphoma Professional Committee • Chinese Follicular Lymphoma Diagnosis and Treatment Guidelines (2013 Edition) [J].
Chinese Journal of Hematology, 2013, 34(9):820-824.
[3] Lossos IS, Gascoyne RD.
Transformation of follicular lymphoma [J].
Best Pract Res Clin Haematol, 2011, 24 (2):147-163.
[4] Rivas-Delgado A, Magnano L, Moreno-Velazquez M, et al.
Response duration and survival shorten after each relapsein patients with follicular lymphoma treated in the rituximabera [J].
Br J Haematol , 2019, 184(5):753 -759.
[5] Tobin JWD, Keane C, Gunawardana J, et al.
Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration [J].
Clin Oncol, 2019, 37(34): 3300-3309.
[6] Freedman A.
Follicular lymphoma: 2018 update on diagnosis and management [J].
Am J Hematol, 2018, 93(2): 296 -305.
[7] Vyas P .
Pathology and genetics:tumours of haematopoietic and lymphoid tissues [J].
Lancet Oncol, 2001, 2(1):770.
[8] Yavas, Ayaz S, Kose SK, et al.
Influence of blood collection systems on coagulation tests [J].
Turk J Haematol, 2012, 29(4): 367 -375.
[9] Pina-Oviedo S, Wang W, Vicknair E,et al.
Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells [J] Pathology, 2017, 49(5):544.
Shanghai Yingli Pharmaceutical Co.
, Ltd.
Shanghai Yingli Pharmaceutical Co.
, Ltd.
was established in 2011 in the National Biomedical Industry Base of Zhangjiang High-tech Park, Shanghai.
It is a technologically innovative biological Pharmaceutical companies.
Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells [J].
Pathology, 2017, 49(5):544.
Shanghai Yingli Pharmaceutical Co.
, Ltd.
Shanghai Yingli Pharmaceutical Co.
, Ltd.
was established in 2011 Located in the National Biomedical Industry Base of Zhangjiang Hi-Tech Park, Shanghai, it is a technologically innovative biomedical enterprise.
Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells [J].
Pathology, 2017, 49(5):544.
Shanghai Yingli Pharmaceutical Co.
, Ltd.
Shanghai Yingli Pharmaceutical Co.
, Ltd.
was established in 2011 Located in the National Biomedical Industry Base of Zhangjiang Hi-Tech Park, Shanghai, it is a technologically innovative biomedical enterprise. Based on the research and development concept of “research and development of domestic first-class and internationally leading innovative drugs”, the company is committed to the research and development of clinically unsatisfied drugs and focuses on the research and development of chemical laboratory with independent intellectual property rights for the treatment of cancer, autoimmune diseases and metabolic diseases.
Molecular innovative drugs, and strive to become an innovative biomedical company with international influence.
At present, the new anti-tumor drug Linperlisib (YY-20394) developed by Yingli Pharmaceutical is used to treat relapsed or refractory follicular lymphoma, and it has obtained the CDE breakthrough treatment product certification, making Yingli Pharmaceutical the second in the country and the first in Shanghai.
A pharmaceutical company that has been recognized as a "breakthrough treatment product" drug.
As a result, Yingli Pharmaceutical has stood out from many new drug R&D and innovative companies, and has become the original innovation in the field of small molecule anti-tumor new drugs.
Since its establishment, the company has established an efficient new drug research and development team, and has developed a number of high-quality pre-clinical and clinical research innovative drugs.
Contact: (86)21-50200566 Website: APP "Points New Game" The company enjoys the database over-value permissions, one disease, one picture | The competitive landscape of acne clinical use late A new breakthrough in breast cancer treatment, the first domestic new epothilone anti-cancer drug, Utidelone, was approved for the marketed drug crystal form patent.
Classic case: Tiotropium Bromide (CPTC VS Boehringer Ingelheim) Unlock your palm immediately professional tools!
On March 29, 2021 Beijing time, Shanghai Yingli Pharmaceutical Co.
, Ltd.
(abbreviated as Yingli Pharmaceutical) announced that its self-developed new drug Linperlisib for the treatment of relapsed/refractory follicular lymphoma phase 2 registration clinical trial has been completed.
The test results show that Linperlisib has achieved statistical and clinical significance improvements in terms of effectiveness and safety for the intention-to-treat population.
Outcome 1: Linperlisib is highly effective in treating relapsed/refractory follicular lymphoma Linperlisib has shown significant clinical benefits in subjects with relapsed/refractory follicular lymphoma.
The results of independent data evaluation (according to the evaluation standard IRWG for lymphoma efficacy) showed that Linperlisib had an ORR of over 80% in 89 patients (evaluable cases) with relapsed/refractory follicular lymphoma, and the disease control rate (DCR) Up to 95% or more.
Dr.
Xu Zusheng, President of R&D of Yingli Pharmaceuticals, said: “We are very excited to observe that Linperlisib has demonstrated extraordinary therapeutic effects in the treatment of relapsed/refractory follicular lymphoma.
The performance in the tumor clinical research project is full of confidence.
We look forward to bringing this Zhangjiang original
PI3Kδ inhibitor drug to patients around the world.
The result 2: Linperlisib is safe, controllable and well tolerated.
From the analysis of statistical results, Linperlisib oral administration is safe, controllable and well tolerated.
Common gastrointestinal adverse reactions such as nausea and similar drugs are especially concerned about the incidence of adverse reactions such as diarrhea and liver toxicity, which are lower than those reported in the literature of the same target drugs.
Compared with traditional therapies, Linperlisib did not find side effects such as vomiting, alopecia, phlebitis, and cardiotoxicity, and rarely caused severe reduction of whole blood cells (neutrophils <0.
5×10^9/L, hemoglobin <60g/L , And platelets <20×10^9/L), the medication process generally does not require hospitalization for monitoring, and it is convenient to carry, which greatly improves the quality of life of patients.
Dr.
Bao Hanying, vice president of the clinical department of Yingli Pharmaceuticals, said: “There is no PI3Kδ inhibitor on the market in China.
The results of this phase 2 clinical trial show that Linperlisib is not only effective, but also gastrointestinal discomfort (diarrhea, nausea, etc.
), The incidence of adverse reactions such as elevated liver enzymes, hypertension, and hyperglycemia is also lower than the previous safety data of this type of drug.
We hope that this new PI3Kδ inhibitor can improve the condition of patients suffering from FL .
"blood Diseases hospital, Chinese Academy of Medical Sciences Professor Qiu Lugui said:" follicular lymphoma (FL) is the world's second most common type of lymphoma, indolent lymphoma is the most common, the incidence rate in non-Hodgkin's lymphoma Second to diffuse large B-cell lymphoma, it is easy to transform into diffuse large B-cell lymphoma and has a very high recurrence rate after remission.
In recent years, immunochemotherapy has gradually replaced chemotherapy and radiotherapy, and has shown good results for different types of lymphoma Clinical treatment effect, but its safety, persistence of drug effect and tumor indication selection are still facing bottlenecks.
Linperlisib's phase 2 clinical trial for the treatment of relapsed/refractory follicular lymphoma has achieved gratifying results, which also indicate this The new PI3Kδ selective inhibitor is expected to bring a new therapy for people suffering from this serious disease, and bring hope to these patients and their families.
" Linperlisib clinical research status Yingli Pharmaceutical plans to treat relapsed/refractory follicles with Linperlisib The results of the Phase 2 clinical trial of sexual lymphoma are communicated with multiple regulatory agencies around the world, and the data will be gradually announced.
Linperlisib received two orphan drug qualifications (CLL/SLL, FL) from the U.
S.
FDA in October 2018, and was approved to conduct Phase II clinical studies in the United States in May 2020; it was approved by China's NMPA (National Medical Products Administration) in September 2020 ) Identification of breakthrough therapy, based on this identification, the market application of this product for the treatment of relapsed/refractory follicular lymphoma can pass the priority review review and approval process to reduce the first round of review time from the 200 required for routine review.
The day is shortened to 130 days[1], which means that Linperlisib is expected to be marketed as soon as possible.
At the same time, Linperlisib's application for breakthrough therapy in the United States is also proceeding simultaneously.
A total of 10 Linperlisib clinical trials are currently being carried out in China and globally.
Linperlisib's completed and ongoing clinical trials include: Linperlisib's tolerability and pharmacokinetics in patients with relapsed or refractory B-cell hematological malignancies Phase I clinical study (China, N=25) Linperlisib in the treatment of relapsed and/ Or a single-arm, open, multi-center phase II clinical trial of patients with refractory follicular lymphoma (China, N=93) A single-arm, open, multi-center phase Ib clinical trial of Linperlisib in patients with advanced solid tumors (China, N =79) A phase Ib clinical trial of Linperlisib in the treatment of patients with relapsed and/or refractory peripheral T-cell lymphoma (China, N=39) A phase I clinical trial of material balance and biotransformation of Linperlisib in Chinese adult male healthy volunteers ( China, N=6) A single-center, randomized, open, 2-sequence, 2-cycle clinical study to evaluate the effects of a high-fat and high-calorie diet on the pharmacokinetics of a single oral administration of Linperlisib tablets in healthy volunteers (China, N=14) Linperlisib treatment Phase Ib clinical study of patients with relapsed and/or refractory B-cell hematological malignancies (China, N=40) Linperlisib combined with GEMOX in the treatment of patients with relapsed and/or refractory diffuse large B-cell lymphoma Center Phase 1b, Phase 2 clinical trial (China, N=28) A single-arm, open, multi-center phase II clinical trial of the efficacy and safety of Linperlisib in patients with relapsed and/or refractory peripheral T/NK cell lymphoma (China, not yet enrolled) Linperlisib is a single-arm, open, multi-center phase II clinical trial for patients with relapsed and/or refractory follicular lymphoma (United States, not yet enrolled) About Linperlisib Linperlisib is an oral PI3Kδ inhibitor, It is a Class 1 new drug developed by Shanghai Yingli Pharmaceutical Co.
, Ltd.
Preclinical data show that it can reduce the phosphorylation level of AKT protein by inhibiting the expression of PI3Kδ protein, thereby inducing cell apoptosis and inhibiting the proliferation of malignant B cells and primary tumor cell lines.
Linperlisib is currently undergoing clinical studies in addition to single-drug treatment for the study population, but also combined with other anti-tumor drugs, such as Linperlisib combined with GEMOX for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.
About YY-20394-002 The single-arm, open, multi-center phase II clinical trial of Linperlisib in the treatment of patients with relapsed and/or refractory follicular lymphoma aims to evaluate the effectiveness and safety of such patients.
The primary research endpoint is the overall response rate (ORR), which is assessed by the Independent Data Evaluation Committee (IRC); the secondary research endpoints include ORR (assessed by the investigator); duration of response (DOR); progression-free survival (PFS); 6 Monthly PFS rate; 12-month PFS rate; survival time (OS); disease control rate (DCR); time to response (TTR) and drug safety.
In the two-year-long trial, a total of 93 cases of relapsed and/or refractory follicular lymphoma that had progressed after receiving second-line or higher systemic treatment (receiving rituximab and at least one alkylating agent) were included patient.
From the analysis of statistical results, Linperlisib oral administration is safe, controllable and well tolerated.
Common gastrointestinal adverse reactions such as nausea and similar drugs pay special attention to the incidence of adverse reactions such as diarrhea and liver toxicity, which are lower than those reported in the literature of the same target drugs.
Compared with traditional therapies, Linperlisib did not find side effects such as vomiting, alopecia, phlebitis, and cardiotoxicity, and rarely caused severe reduction of whole blood cells (neutrophils <0.
5×10^9/L, hemoglobin <60g/L , And platelets <20×10^9/L), the medication process generally does not need to be hospitalized for monitoring, and it is convenient to carry, which greatly improves the patient’s quality of life.
About Follicular Lymphoma (FL) Follicular lymphoma (FL) is a type of indolent non-Hodgkin's lymphoma (NHL) that originates in the follicular germinal center.
In my country, FL accounts for about 8.
1%~23.
5% of NHL, the median age of onset is 55~60 years old, and the incidence of women is slightly higher than that of men [2].
The disease progresses indolently, with a median survival of up to more than 10 years, but most diseases will eventually relapse or transform, and they still cannot be cured [3].
Research in 2018 showed that the survival of patients decreased significantly with the increase in the number of recurrences [4].
According to statistics, nearly 15% of patients in FL do not need treatment after the onset of disease, and nearly 20% of patients are refractory FL, with a very short survival period [5, 6]; in addition, nearly 30% of patients will Transformation into highly aggressive lymphoma is clinically manifested as the rapid progression of the disease and requires high-intensity treatment [7, 8].
At present, the first and second-line regimens for FL treatment recommended by major guidelines mainly target CD20 monoclonal antibody-based immunochemotherapy regimens, followed by CD20 monoclonal antibody maintenance treatment, and some relapsed patients can further obtain long-term survival through autologous stem cell transplantation.
[9].
In recent years, the "no chemotherapy" regimen for FL has attracted more and more attention because of its definite efficacy and low toxicity.
Current research hotspots for relapsed/refractory FL are new targeted drugs and immunotherapy, including PI3K inhibitors, BCL2 inhibitors, EZH2 inhibitors, bispecific antibodies, chimeric antigen receptor T cell (CAR-T) therapy, etc.
. Reference materials: [1] State Administration for Market Regulation, Drug Registration Management Measures (2020 Edition).
[2] Chinese Medical Association Hematology Branch, Chinese Anti-Cancer Association Lymphoma Professional Committee • Chinese Follicular Lymphoma Diagnosis and Treatment Guidelines (2013 Edition) [J].
Chinese Journal of Hematology, 2013, 34(9):820-824.
[3] Lossos IS, Gascoyne RD.
Transformation of follicular lymphoma [J].
Best Pract Res Clin Haematol, 2011, 24 (2):147-163.
[4] Rivas-Delgado A, Magnano L, Moreno-Velazquez M, et al.
Response duration and survival shorten after each relapsein patients with follicular lymphoma treated in the rituximabera [J].
Br J Haematol , 2019, 184(5):753 -759.
[5] Tobin JWD, Keane C, Gunawardana J, et al.
Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration [J].
Clin Oncol, 2019, 37(34): 3300-3309.
[6] Freedman A.
Follicular lymphoma: 2018 update on diagnosis and management [J].
Am J Hematol, 2018, 93(2): 296 -305.
[7] Vyas P .
Pathology and genetics:tumours of haematopoietic and lymphoid tissues [J].
Lancet Oncol, 2001, 2(1):770.
[8] Yavas, Ayaz S, Kose SK, et al.
Influence of blood collection systems on coagulation tests [J].
Turk J Haematol, 2012, 29(4): 367 -375.
[9] Pina-Oviedo S, Wang W, Vicknair E,et al.
Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells [J] Pathology, 2017, 49(5):544.
Shanghai Yingli Pharmaceutical Co.
, Ltd.
Shanghai Yingli Pharmaceutical Co.
, Ltd.
was established in 2011 in the National Biomedical Industry Base of Zhangjiang High-tech Park, Shanghai.
It is a technologically innovative biological Pharmaceutical companies.
Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells [J].
Pathology, 2017, 49(5):544.
Shanghai Yingli Pharmaceutical Co.
, Ltd.
Shanghai Yingli Pharmaceutical Co.
, Ltd.
was established in 2011 Located in the National Biomedical Industry Base of Zhangjiang Hi-Tech Park, Shanghai, it is a technologically innovative biomedical enterprise.
Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells [J].
Pathology, 2017, 49(5):544.
Shanghai Yingli Pharmaceutical Co.
, Ltd.
Shanghai Yingli Pharmaceutical Co.
, Ltd.
was established in 2011 Located in the National Biomedical Industry Base of Zhangjiang Hi-Tech Park, Shanghai, it is a technologically innovative biomedical enterprise. Based on the research and development concept of “research and development of domestic first-class and internationally leading innovative drugs”, the company is committed to the research and development of clinically unsatisfied drugs and focuses on the research and development of chemical laboratory with independent intellectual property rights for the treatment of cancer, autoimmune diseases and metabolic diseases.
Molecular innovative drugs, and strive to become an innovative biomedical company with international influence.
At present, the new anti-tumor drug Linperlisib (YY-20394) developed by Yingli Pharmaceutical is used to treat relapsed or refractory follicular lymphoma, and it has obtained the CDE breakthrough treatment product certification, making Yingli Pharmaceutical the second in the country and the first in Shanghai.
A pharmaceutical company that has been recognized as a "breakthrough treatment product" drug.
As a result, Yingli Pharmaceutical has stood out from many new drug R&D and innovative companies, and has become the original innovation in the field of small molecule anti-tumor new drugs.
Since its establishment, the company has established an efficient new drug research and development team, and has developed a number of high-quality pre-clinical and clinical research innovative drugs.
Contact: (86)21-50200566 Website: APP "Points New Game" The company enjoys the database over-value permissions, one disease, one picture | The competitive landscape of acne clinical use late A new breakthrough in breast cancer treatment, the first domestic new epothilone anti-cancer drug, Utidelone, was approved for the marketed drug crystal form patent.
Classic case: Tiotropium Bromide (CPTC VS Boehringer Ingelheim) Unlock your palm immediately professional tools!
